Acute severe ulcerative colitis (ASUC) in pregnancy poses a clinical challenge with significant risk to both mother and fetus. Anti-TNF alpha therapy is known to be safe in pregnancy, however, data surrounding outcomes in ASUC is limited. In this report, we present the case of a pregnant patient of 10 weeks' gestation with ASUC successfully managed with intensified and accelerated infliximab therapy for a total dose of 35 mg/kg during a single admission. This case highlights the use of this therapeutic strategy, as a part of a multidisciplinary approach, to avoid the need for a high-risk colectomy.
Keywords: clinical intestinal disorders; gastroenterology; immunology; microbiology and inflammatory bowel diseases.
© 2025 The Author(s). JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.